Mercè Marzo-Castillejo

Mercè Marzo-Castillejo

Auto-generated profile, based on publicly available information

Mercè Marzo-Castillejo

Unitat de Suport a la Recerca Metropolitana Sud, IDIAP Jordi Gol, Direcció d'Atenció Primària Costa de Ponent, Institut Català de la Salut, Barcelona, España

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in Gastroenterología y Hepatología
Verified
Journal Article
Closed access
Joaquin CubiellaJoaquin Cubiella
Joaquin Cubiella
MMMercè Marzo-Castillejo
Mercè Marzo-Castillejo
JMJuan José Mascort-Roca
Juan José Mascort-Roca
FAFrancisco Javier Amador-Romero
Francisco Javier Amador-Romero
BBBegoña Bellas-Beceiro
Begoña Bellas-Beceiro
PVPablo Vega-Villaamil
Pablo Vega-Villaamil

22 January 2001 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
XBXavier Bonfill
Xavier Bonfill
MCMercè Marzo Castillejo
Mercè Marzo Castillejo
MVManel Pladevall Vila
Manel Pladevall Vila
JMJoan Marti
Joan Marti
JEJosé I Emparanza
José I Emparanza

1 January 2015 in Atencion Primaria
Verified
Journal Article
Open access
ASAndrea Juliana Sanabria
Andrea Juliana Sanabria
DRDavid Rigau
David Rigau
RRRafael Rotaeche
Rafael Rotaeche
ASAnna Selva
Anna Selva
MMMercè Marzo-Castillejo
Mercè Marzo-Castillejo
PAPablo Alonso
Pablo Alonso
Clinical practice guidelines (CPG) provide recommendations on the benefits and harms of different healthcare interventions. Proper CPG development and implementation can potentially reduce variability in clinical practice while improving its quality and safety. The GRADE system is used to assess the quality of evidence and to grade the strength of recommendations in the context of the development of CPGs, systematic reviews or health technology assessments. The aim of this article is to describe the main characteristics of the GRADE system through relevant examples in the context of primary care.

18 May 2021 in BMJ Open
Verified
Journal Article
Open access
PDF file
ECErmengol Coma
Ermengol Coma
CGCarolina Guiriguet
Carolina Guiriguet
NMNuria Mora
Nuria Mora
MMMercè Marzo-Castillejo
Mercè Marzo-Castillejo
MBMencia Benítez
Mencia Benítez
MMManuel Medina
Manuel Medina
Objective Cancer care has been disrupted by the response of health systems to the COVID-19 pandemic, especially during lockdowns. The objective of our study is to evaluate the impact of the pandemic on the incidence of cancer diagnoses in primary care. Design Time-series study of malignant neoplasms and diagnostic procedures, using data from the primary care electronic health records from January 2014 to September 2020. Setting Primary care, Catalonia, Spain. Participants People older than 14 years and assigned in one of the primary care practices of the Catalan Institute of Health with a new diagnosis of malignant neoplasm. Main outcome measures We obtained the monthly expected incidence of malignant neoplasms using a temporary regression, where the response variable was the incidence of cancer from 2014 to 2018 and the adjustment variables were the trend and seasonality of the time series. Excess or lack of malignant neoplasms was defined as the number of observed minus expected cases, globally and stratified by sex, age, type of cancer and socioeconomic status. Results Between March and September 2020 we observed 8766 (95% CI 4135 to 13 397) fewer malignant neoplasm diagnoses, representing a reduction of 34% (95% CI 19.5% to 44.1%) compared with the expected. This underdiagnosis was greater in individuals aged older than 64 years, men and in some types of cancers (skin, colorectal, prostate). Although the reduction was predominantly focused during the lockdown, expected figures have not yet been reached (40.5% reduction during the lockdown and 24.3% reduction after that). Conclusions Reduction in cancer incidence has been observed during and after the lockdown. Urgent policy interventions are necessary to mitigate the indirect effects of the COVID-19 pandemic and related control measures on other diseases and some strategies must be designed in order to reduce the underdiagnosis of cancer.

7 August 2017 in BMC Cancer
Verified
Journal Article
Open access
PDF file
CGCarolina Guiriguet
Carolina Guiriguet
GPGuillem Pera
Guillem Pera
ACAntoni Castells
Antoni Castells
Pere Torán-MonserratPere Torán-Monserrat
Pere Torán-Monserrat
JGJaume Grau
Jaume Grau
MMMercedes Marzo-Castillejo
Mercedes Marzo-Castillejo
There is controversy regarding how comorbidity impacts on colorectal cancer screening, especially in the context of organised programmes. The aim of this study is to assess the effect of comorbidities on participation in the Barcelona population-based colorectal cancer screening programme (BCCSP). Cross-sectional study carried out in ten primary care centres involved in the BCCSP. Individuals aged 50 to 69, at average risk of colorectal cancer, who were invited to participate in the first round of the faecal immunochemical test-based BCCSP were included (2011–2012). The main variable was participation in the BCCSP. Comorbidity was assessed by clinical risk group status. Other adjusting variables were age, sex, socioeconomic deprivation, visits to primary care, smoking, alcohol consumption and body mass index. Logistic regression models were used to test the association between participation in the programme and potential explanatory variables. The results were given as incidence rate ratios (IRR) and their 95% confidence intervals (CI). Of the 36,208 individuals included, 17,404 (48%) participated in the BCCSP. Participation was statistically significantly higher in women, individuals aged 60 to 64, patients with intermediate socioeconomic deprivation, and patients with more medical visits. There was a higher rate of current smoking, high-risk alcohol intake, obesity and individuals in the highest comorbidity categories in the non-participation group. In the adjusted analysis, only individuals with multiple minor chronic diseases were more likely to participate in the BCCSP (IRR 1.14; 95% CI [1.06 to 1.22]; p < 0.001). In contrast, having three or more dominant chronic diseases was associated with lower participation in the screening programme (IRR 0.76; 95% CI [0.65 to 0.89]; p = 0.001). Having three or more dominant chronic diseases, was associated with lower participation in a faecal immunochemical test-based colorectal cancer screening programme, whereas individuals with multiple minor chronic diseases were more likely to participate. Further research is needed to explore comorbidity as a cause of non-participation in colorectal cancer screening programmes and which individuals could benefit most from colorectal cancer screening.

1 April 2017 in Gastroenterología y Hepatología
Verified
Journal Article
Closed access
JSJordi Serra
Jordi Serra
JMJuanjo Mascort-Roca
Juanjo Mascort-Roca
MMMercè Marzo-Castillejo
Mercè Marzo-Castillejo
SASilvia Delgado Aros
Silvia Delgado Aros
JSJuan Ferrándiz Santos
Juan Ferrándiz Santos
FMFermín Mearin Manrique
Fermín Mearin Manrique